In early May 2026, enGene Therapeutics reported interim Phase 2 LEGEND trial data for its bladder cancer candidate detalimogene voraplasmid, showing a 54% complete response rate but weaker durability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results